Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
ENAH pseudogene 1 (ENAHP1) is a **pseudogene**, which means it is a non-functional genomic sequence resembling the functional ENAH (enabled homolog) gene. Pseudogenes like ENAHP1 arise from gene duplication or retrotransposition events that result in loss of protein-coding ability due to mutations. While some pseudogenes can function through regulatory RNA activity, the specific biological or clinical roles of ENAHP1 have not been described in the scientific literature[2][3]. Unlike its functional parental gene, ENAH, which encodes an actin cytoskeleton regulator protein, ENAHP1 does not produce a protein and is not implicated as a therapeutic target, biomarker, or disease gene. If you need structured data: - ENAH pseudogene 1 does not fit the usual profile of a "target molecule/receptor". - There is currently no evidence supporting a therapeutic, biomarker, or regulatory role for ENAHP1. If you seek information about the functional ENAH gene/protein (Enabled homolog), clarification would be needed, as the pseudogene itself (ENAHP1) is non-functional.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on ENAH pseudogene 1 (ENAHP1).